ライフサイエンスコーパス: PCV7

1 PCV7 induced a low ability to opsonize different isolate

2 PCV7 induces a greater functional antibody response than

3 PCV7 ineffectiveness against serotype 19A, antibiotic re

4 PCV7 introduction has led to reductions in serotype 6A I

5 PCV7 introduction resulted in 83% (95% CI, 66%-91%, P <

6 PCV7 serotypes decreased by 76% overall (103 versus 25 p

7 PCV7-serotype IPD declined among all race, age, and PPV2

8 PCV7-type IPD rates in all ages in both races decreased

9 ious analysis to 6.5 years after the "3 + 0" PCV7 schedule was introduced in Australia in 2005.

10 A 2 + 1 PCV7 schedule was effective in preventing vaccine-seroty

11 We estimated the effectiveness of >/=2 PCV7 doses against invasive pneumococcal disease (IPD) i

12 Effectiveness of >/=2 PCV7 doses against vaccine-serotype IPD was 74% (95% con

13 at before (1998-2000) and during (2001-2002) PCV7 introduction.

14 In 2006-2007, PCV7 types caused 2% of IPD cases, and the 6 additional

15 erotypes (4, 6B, 9V, 14, 18C, 19F, and 23F), PCV7-related serotypes (6A, 9A, 9L, 9N, 18A, 18B, 18F, 1

16 Priming with 1, 2, or 3 PCV7 doses during infancy did not affect serotype-specif

17 19F, and similar or lower responses for 6/7 PCV7 serotypes.

18 alysis population included 881 PCV13 and 873 PCV7 recipients.

19 Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using

20 OM rates decreased, along with an additional PCV7 + 6A OM reduction.

21 tions increased from 51% before to 61% after PCV7 introduction (P < .0001).

22 o PCV7 serotypes decreased in all ages after PCV7 introduction (P < .001), whereas the incidence of I

23 nce and carriage prevalence before and after PCV7 introduction to estimate changes in serotype-specif

24 We compared rates before and after PCV7 use by age, race, PPV23 indication, and serotype.

25 f serotype-specific disease before and after PCV7 was licensed for use.

26 Of the 256 cases diagnosed after PCV7 introduction, 23% (n = 60) had been born before 37

27 Dramatic reductions in IPD after PCV7 introduction in the United States remain evident 7

28 n serotype-specific invasive potential after PCV7 introduction.

29 of PCV13 disease, was observed shortly after PCV7/PCV13 introduction.

30 cific IPD changes among multiple sites after PCV7 introduction.

31 data >/= 2 years before and >/= 1 year after PCV7 introduction.

32 quickly and were sustained for 7 years after PCV7 introduction, supporting use of PCVs.

33 Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95%

34 a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additional serotypes (PCV6+).

35 n H. influenzae and S. aureus carriage among PCV7 recipients.

36 AOM and after exposure to antimicrobials and PCV7, which is mainly attributable to reduced prevalence

37 [CI], 12.0-14.0) per 100 000 live births and PCV7 serotypes accounted for 44% (154/349) of serotyped

38 Overall and PCV7-type IPD incidence declined by 45% (from 24.4 to 13

39 d outcomes of IPD in children with PCV13 and PCV7 vaccine failure.

40 The vaccine effectiveness for PCV13 and PCV7 was lower than predicted by the aggregate correlate

41 ease were serotype 19F, present in PCV13 and PCV7, and serotypes 6A and 19A, present in PCV13 only.

42 ve pressures of widespread macrolide use and PCV7 and PCV13 introductions on S. pneumoniae were assoc

43 dence in 2007 with that in 1998-1999 (before PCV7) and assessed potential serotype coverage of new co

44 an expected on the basis of the rates before PCV7 was introduced.

45 ttern: In the PCV7 period, only OM caused by PCV7 + 6A serotypes was decreased; in the PCV13 period,

46 mpared with the pre-PCV period, OM caused by PCV7 plus serotype 6A and the 5 additional PCV13 serotyp

47 er 100,000 person-years in disease caused by PCV7 serotypes (-89%; 95% confidence interval [CI], -92

48 Reductions in the rates of disease caused by PCV7 serotypes among both children and adults most likel

49 e of invasive pneumococcal disease caused by PCV7 serotypes decreased by 85% (95% CI, -89 to -79), wh

50 s well as the reduction in disease caused by PCV7 serotypes following the introduction of PCV7 in 200

51 type, 0.16 (0.07-0.40) for disease caused by PCV7 serotypes, 0.17 (0.07-0.42) for disease caused by 1

52 gher proportion of adult IPD cases caused by PCV7 serotypes.

53 ng adults aged >40 years that were caused by PCV7-targeted serotypes.

54 an 86% reduction of the serotypes covered by PCV7 (1.46 vs 0.20 per 100,000; IRR 0.14, 0.10-0.18) and

55 The herd protection induced by PCV7 is continuing, and similar indirect protection is o

56 valence may be explained by the induction by PCV7 of low amounts of functional anti-6C antibody, comp

57 disease that exceeds protection provided by PCV7.

58 e cross-reacting serotype 6C; and the common PCV7 serotype 19F.

59 with the heptavalent pneumococcal conjugate (PCV7) vaccine and rapid tests for identification of viru

60 The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease

61 the 7-valent pneumococcal protein conjugate (PCV7) vaccine, which includes serotypes 4, 6B, 9V, 14, 1

62 of children that did not complete the 4-dose PCV7 series had a higher proportion of adult IPD cases c

63 After 3 vaccine doses, PCV7 and PCV13 failure rates were 0.19/100000 (95% confi

64 ized for eligible children to receive either PCV7 or a meningococcal conjugate vaccine (MCV).

65 Following PCV7 introduction, clinical information was also obtaine

66 P = .004) per 100 000 live births following PCV7 introduction.

67 ibe their clinical characteristics following PCV7 introduction.

68 Replacement disease following PCV7 introduction was mainly due to serotypes 1, 3, 7F,

69 d overall changes in IPD incidence following PCV7 introduction for most studies, while the more detai

70 rotype 19A significantly increased following PCV7's introduction, but the incidence declined toward b

71 ther changes in rates had occurred following PCV7 introduction, we calculated site specific rate rati

72 italizations in children aged <1 y following PCV7 introduction (-18.0%, 95% CI: -22.6%, -13.1%, for 2

73 , 0.12 (0.08-0.20), and 0.18 (0.15-0.21) for PCV7+6A serotypes, 5 additional PCV13 serotypes, and all

74 dible interval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12

75 Young infants have benefited from PCV7 through indirect (herd) protection.

76 uctions in IPD due to vaccine serotypes from PCV7 (IRR, 0.20; CI, .17-.22) were about 2-fold greater

77 n IPD incidence shortly after the shift from PCV7 to PCV13 in the national immunization program.

78 Serum specimens from PCV7-immunized children had median opsonization indices

79 In France, the switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13)

80 ected among children younger than 5 years if PCV7 alone had been continued, incidence of IPD overall

81 ased but remain low relative to decreases in PCV7-type IPD.

82 ed by serotypes included in PCV13 but not in PCV7 decreased from 6.5 to 0.5 per 100 000 in children a

83 ined in the 13-valent PCV (PCV13) but not in PCV7.

84 83% (95% CI, 66%-91%, P < .001) reduction in PCV7 IPD and a declining trend in overall IPD by 2009-20

85 We measured the effects of trends in PCV7-type and non-PCV7-type IPD rates on racial disparit

86 in conjugate (PCV13) vaccine, which includes PCV7 serotypes plus serotypes 1, 3, 5, 6A, 7F, 19A, may

87 Isolates were grouped into PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F), PCV7-

88 The Gambia introduced PCV7 in August, 2009, and PCV13 in May, 2011.

89 95% IE] 59-68) and IPD caused by PCV13 minus PCV7 serotypes declined by 93% (91-94), by July, 2012, t

90 ined by 12-32% and IPD caused by PCV13 minus PCV7 type IPD declined by 58-72%, depending on age.

91 gainst which PCV7 has no effect (PCV13 minus PCV7).

92 and nonsusceptibility to penicillin of non- PCV7 serotypes, and we found increased proportions of sp

93 , 18B, 18F, 19B, 19C, 23A, and 23B), and non-PCV7 serotypes (all others).

94 d the effects of trends in PCV7-type and non-PCV7-type IPD rates on racial disparities in overall IPD

95 sparities in IPD rates persisted because non-PCV7-type IPD rates are higher among blacks.

96 recent increase in meningitis caused by non-PCV7 serotypes, including strains nonsusceptible to anti

97 ingitis and invasive pneumonia caused by non-PCV7 types increased for all age groups (P< .05), wherea

98 s increased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use.

99 The percentages of cases from non-PCV7 serotypes 19A, 22F, and 35B each increased signific

100 ction of PCV7 resulted in an increase in non-PCV7 serotypes, including some not covered by the 13-val

101 disease (IPD) and moderate increases in non-PCV7 type IPD.

102 ever, rates of antibiotic-nonsusceptible non-PCV7-type IPD increased during 2004-2009.

103 per 100,000 live births, while rates of non-PCV7 serotypes remained stable (P = .55).

104 se decreased by 32.1% (P=0.08), rates of non-PCV7-serotype disease increased from 0.32 to 0.51 (an in

105 D rates caused by serotype 19A and other non-PCV7 types have increased but remain low relative to dec

106 of IPD caused by serotype 19A and other non-PCV7 types increased from 0.8 to 2.7 cases per 100,000 p

107 Among the non-PCV7 serogroups, newly emerging clones were uncommon; an

108 the incidence of invasive disease due to non-PCV7 serogroups together with serogroup 19A increased (P

109 During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, de

110 aused by serotypes included in PCV13 but not PCV7 were prevented among children aged <5 years (-97% d

111 cination were extrapolated based on observed PCV7 effects.

112 Nasopharyngeal carriage of PCV7 and 23vPPV serotypes was similar among the groups.

113 Nasopharyngeal carriage of PCV7 serotypes in Group 1 was significantly higher than

114 rains were highly related to other clones of PCV7 serotypes or to isolates within major 19A clonal co

115 During the decade of PCV7 use (2000-2009), MR-IPD decreased rapidly until 200

116 A single dose of PCV7 induced significant increases in serotype-specific

117 the population that received 3 or 4 doses of PCV7 (mean centered), and a linear spline to control for

118 s after they were given two priming doses of PCV7 (n=126) or PCV13 (n=237) and opsonophagocytic antib

119 ), despite receiving at least three doses of PCV7 in the second year of life or two doses in the seco

120 We evaluated the effect of PCV7 on incidence of disease due to nonvaccine serotypes

121 Despite near elimination of PCV7-type IPD in both races, overall disparities in IPD

122 In this study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed.

123 with the observed heterogeneity in impact of PCV7 on childhood all-serotype IPD.

124 are the main determinants for the impact of PCV7 on childhood IPD and can be combined in a simple mo

125 l performance against the reported impact of PCV7 on childhood IPD in high-income countries from a re

126 vaccine serotypes may mitigate the impact of PCV7 on nasopharyngeal bacterial community structure and

127 We aimed at assessing the impact of PCV7/PCV13 sequential introduction on pneumococcal and o

128 eillance project following implementation of PCV7 (in September 2006) and PCV13 (in April 2010) in ch

129 In Utah, the introduction of PCV7 and PCV13 was associated with rapid increases in se

130 PCV7 serotypes following the introduction of PCV7 in 2000.

131 ates has decreased since the introduction of PCV7 in Massachusetts in 2000.

132 Introduction of PCV7 in the Dutch National Immunization Program in 2006

133 Thus, the introduction of PCV7 resulted in an increase in non-PCV7 serotypes, incl

134 stimated for years after the introduction of PCV7 vaccination (2001-2004) were compared with expected

135 997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introdu

136 In the years following introduction of PCV7, a strain of S pneumoniae has emerged in the United

137 in gene diversity after the introduction of PCV7, the accessory gene pool re-expanded mainly by gene

138 during the decade after the introduction of PCV7.

139 persists a decade after the introduction of PCV7.

140 ombination that predated the introduction of PCV7.

141 lonal compositions since the introduction of PCV7.

142 s coded as RSV following the introduction of PCV7.

143 cluded data from an earlier investigation of PCV7 to assess vaccine effectiveness in children exposed

144 ng adults 25 to 44 years of age, the rate of PCV7-serotype disease declined by 57% (95% CI, -63 to -5

145 Although rates of PCV7-related-serotype disease decreased by 32.1% (P=0.08

146 Rates of PCV7-serotype isolates decreased significantly from 7.3

147 Rates of PCV7-serotype meningitis declined from 0.66 case to 0.18

148 Receipt of PCV7 resulted in pneumococcal serotype replacement but d

149 riage to disease before and after rollout of PCV7/13, measured as OM incidence per carrier.

150 f progression to complex OM after rollout of PCV7/13.

151 nontarget groups demonstrates the success of PCV7 and PCV13.

152 during the American Indian clinical trial of PCV7, in which communities were randomized for eligible

153 ALY) lost from the IPD remaining when use of PCV7 stopped in 2010 was estimated for the serotypes cov

154 AOM microbiology has changed with use of PCV7.

155 ere randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91).

156 domly assigned to receive PCV13 (n = 932) or PCV7 (n = 934) at ages 2, 4, 6, or 12 months.

157 was higher than the efficacy of TIV alone or PCV7 alone.

158 For serotype 3, and the other PCV7 serotypes, there were no significant differences be

159 PCV13 has a significant added benefit over PCV7 in reducing carriage of ANSP.

160 he potential additional impact of PCV13 over PCV7 on reducing ANSP carriage.

161 ing the preceding period of heptavalent PCV (PCV7) use, overall and by serotype category.

162 Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with dec

163 least 3 or at least 4 doses of 7-valent PCV (PCV7) from the state immunization registry.

164 The 7-valent PCV (PCV7) was introduced to the Israeli National Immunizatio

165 re and after administration of 7-valent PCV (PCV7) were available from England and Wales, the Netherl

166 serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six addi

167 Three subperiods were defined: pre-PCV, PCV7, and PCV13.

168 Three sub-periods were established: pre-PCV, PCV7, and PCV13.

169 After pediatric PCV7 adoption, the median differential was 24.4% (P < .0

170 Ten years after pediatric PCV7 authorization, IPD due to PCV7 serotypes had decrea

171 ases per 100 000 population before pediatric PCV7 use and 6.4 afterward (P = .52).

172 Both PPV23 and herd immunity from pediatric PCV7 were associated with reductions in IPD in immunocom

173 ype distribution before widespread pediatric PCV7 use, the median differential between the 23 and 13

174 za was circulating, the efficacy of TIV plus PCV7 was 72.4% (95% confidence interval, 30.2%-89.1%) ag

175 rs old, overall IPD decreased by year 1 post-PCV7 (RR 0.55, 95% CI 0.46-0.65) and remained relatively

176 e-PCV7 (July 1998 to December 2004) and post-PCV7 (January 2005 to June 2011) periods, adjusting for

177 observed by expected IPD rates for each post-PCV7 year.

178 re-PCV7 period to obtain an estimate of post-PCV7 disease incidence.

179 increased (41%-43% vs 56%-57%) pre- vs post-PCV7.

180 of 23% in all-cause pneumonia 7-9 years post-PCV7 introduction reported for adults aged >/=85 years i

181 Relative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years for 6 of

182 and June, 2014, versus the pre-PCV13 and pre-PCV7 baseline.

183 modeling of pre-PCV7 rates or averaging pre-PCV7 rates.

184 ic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults >/=65 years old.

185 nded mainly by genes already circulating pre-PCV7.

186 ared with expected rates calculated from pre-PCV7 years (1997-1999).

187 ng either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates.

188 and meta-analysis to obtain the odds of pre-PCV7 VT carriage in the respective settings.

189 The odds of pre-PCV7 VT IPD, PCV schedule, PCV coverage and whether a ca

190 spitalization rates by age group for the pre-PCV7 (July 1998 to December 2004) and post-PCV7 (January

191 When compared with the pre-PCV7 baseline, there was a 56% overall reduction in inva

192 f IPD caused by each serotype during the pre-PCV7 period to obtain an estimate of post-PCV7 disease i

193 The pre-PCV7 proportion of VT carriage and IPD are the main dete

194 The pre-PCV7 proportion of VT IPD alone also had limited predict

195 thy infants were randomized (1:1) to receive PCV7 or PCV13 at ages 2, 4, 6, and 12 months; NP swabs w

196 Both group 2 and 3 received PCV7 at 2, 3 and 4 months.

197 rol group and comprised infants who received PCV7 after 6 months and came from unvaccinated communiti

198 trains that caused AOM in children receiving PCV7 between September 2003 and June 2006.

199 ected to have an indirect effect of reducing PCV7 serotype maternal colonization and possibly disease

200 South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule.

201 have been expected if PCV13 had not replaced PCV7.

202 In 2010, PCV13 replaced PCV7 in the US immunisation schedule.

203 A 13-valent vaccine (PCV13) replaced PCV7 in 2010.

204 of age; a 13-valent vaccine (PCV13) replaced PCV7 in 2011.

205 umococcal conjugate vaccine (PCV13) replaced PCV7.

206 countries replacing or considering replacing PCV7 with PCV13, as well as data that can be used to eva

207 umococcal disease incidence, while replacing PCV7 with PCV13 would cause an overall decrease.

208 ly in children <3 years following sequential PCV7/PCV13 introduction.

209 nation against seven pneumococcal serotypes (PCV7) reduced disease prevalence due to antibiotic-resis

210 ve decreased among children and adults since PCV7 was introduced.

211 riage prevalence decreased in all ages since PCV7 introduction; vaccine-serotype carriage has been ne

212 ition and prevalence of NP colonization than PCV7 did for 4 additional PCV13 serotypes, and serotypes

213 This study indicates that PCV7 may have an immunological advantage over 23vP in ad

214 Subsequent studies showed that PCV7 provided cross-protection against serotype 6A but n

215 accine effectiveness was 90% (34-98) for the PCV7 serotypes and 73% (55-84) for the six additional se

216 D due to serotype 6C disease expanded in the PCV7 era.

217 ], respectively) in a 2-step pattern: In the PCV7 period, only OM caused by PCV7 + 6A serotypes was d

218 rotection) and also showed a reversal of the PCV7 era increase in paediatric empyema related to strai

219 The highly effective introduction of the PCV7 pneumococcal vaccine in 2000 in the United States(2

220 Since the introduction of the PCV7 vaccine, the incidence of true bacteremia has decre

221 decrease in the rate of bacteremia since the PCV7 vaccine was introduced means that the management gu

222 y lower in the PCV13 group compared with the PCV7 group; the main serotypes contributing to this sign

223 Over the same timeframe, PCV7 serotype disease incidence declined to </=1 case pe

224 nd no evidence of pneumococcal adaptation to PCV7 via downregulation or deletion of vaccine-serotype

225 PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 serotypes are more

226 cteristics, or outcomes of PCV13 compared to PCV7 vaccine failure.

227 nvasive pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F).

228 The incidence of IPD due to PCV7 serotypes decreased in all ages after PCV7 introduc

229 ter pediatric PCV7 authorization, IPD due to PCV7 serotypes had decreased by 90% (95% CI, 77%-96%) in

230 1-2013, the overall incidences of IPD due to PCV7 serotypes, the 6 additional serotypes in PCV13, and

231 odeficiency virus were more often exposed to PCV7 serotypes by their mothers, their risk of acquisiti

232 creasing trend in disease incidence prior to PCV7 introduction in England and Wales, and (ii) a range

233 Prior to PCV7 introduction, IPD incidence in infants aged <90 day

234 to confirm an adequate antibody response to PCV7.

235 indings provide reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent tr

236 ad use of the pneumococcal conjugate vaccine PCV7.

237 7), 7-valent pneumococcal conjugate vaccine (PCV7) (2008-2010), and PCV13 (2011-2013) periods were es

238 ith 7-valent pneumococcal conjugate vaccine (PCV7) accounted for 25% of UAD-positive isolates.

239 the 7-valent pneumococcal conjugate vaccine (PCV7) based on serological noninferiority criteria.

240 seven-valent pneumococcal conjugate vaccine (PCV7) began in the USA in 2000.

241 sal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 20

242 of 7-valent pneumococcal conjugate vaccine (PCV7) has led to significant reductions in disease while

243 heptavalent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of pneumococc

244 f a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vac

245 heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced macrolide-resistant invasive pneum

246 heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its effect on pneumococcal meningitis

247 of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among adults has decline

248 ric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

249 st offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a boos

250 ced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 using a 2 + 1 schedule (6 and 14 wee

251 ogenicity of the 7-valent conjugate vaccine (PCV7) in children and the 23-valent polysaccharide vacci

252 the 7-valent pneumococcal conjugate vaccine (PCV7) in September 2006 has markedly reduced the burden

253 of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs.

254 the pneumococcal 7-valent conjugate vaccine (PCV7) into the routine infant immunization schedule in E

255 of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2

256 the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants

257 seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial compone

258 the 7-valent pneumococcal conjugate vaccine (PCV7) on the carriage of serotype 6C is unknown.

259 pread use of pneumococcal conjugate vaccine (PCV7) resulted in decreases in invasive disease among ch

260 Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other than 19A accounted for 40% of thes

261 the 7-valent pneumococcal conjugate vaccine (PCV7) transmitted by their mothers than vice versa; howe

262 n a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

263 of 7-valent pneumococcal conjugate vaccine (PCV7) use in US children.

264 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococcal nasopharyngeal carriage and se

265 , a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 with a three-dose schedule

266 seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic

267 seven-valent pneumococcal conjugate vaccine (PCV7) were associated with changes in the rate of hospit

268 the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly base

269 of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates among b

270 of 7-valent pneumococcal conjugate vaccine (PCV7).

271 roduction of the 7-valent conjugate vaccine (PCV7).

272 f a pneumococcal 7-valent conjugate vaccine (PCV7).

273 pneumococcal seven-valent conjugate vaccine (PCV7).

274 of 7-valent pneumococcal conjugate vaccine (PCV7).

275 of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by 23-valent pneumoco

276 he 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic population of Streptococc

277 uction of the 7-valent pneumococcal vaccine (PCV7) are sparse, especially in adults.

278 ent protein-conjugated pneumococcal vaccine (PCV7) introduction (139 versus 55 per 2-year period prio

279 mothers) plus 7-valent pneumococcal vaccine (PCV7; delivered to infants) was higher than the efficacy

280 jugated pneumococcal polysaccharide vaccine (PCV7) is safe and induced greater serotype-specific immu

281 jugated pneumococcal polysaccharide vaccine (PCV7) were also associated with reduced prevalence of di

282 vaccine (PCV13) replaced a 7-valent vaccine (PCV7) that contained all PCV7 serotypes plus 6 additiona

283 se in The Gambia where the 7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13

284 immunisation with the seven-valent vaccine (PCV7), but its potential for herd protection and serotyp

285 on established for the seven-valent vaccine (PCV7).

286 d 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altered pneumococcal serot

287 d 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are highly effective in pr

288 d 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).

289 ood immunization programs in 2002 (7-valent [PCV7]) and 2010 (13-valent [PCV13]).

290 nd trial compared the impact of PCV13 versus PCV7 on nasopharyngeal (NP) colonization and immunogenic

291 igated B-cell responses to establish whether PCV7 (a 7-valent PCV) induced T-dependent responses in a

292 caused by the PCV13 serotypes against which PCV7 has no effect (PCV13 minus PCV7).

293 STs commonly associated with PCV7 serotypes declined following PCV implementation, wi

294 The proportion of adult carriers with PCV7-type pneumococcal carriage decreased from 28% of ca

295 It was comparable with PCV7 for all other common serotypes.

296 ly from those causing invasive disease, with PCV7-associated serotypes overrepresented.

297 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV

298 ons learned from a decade of experience with PCV7, the increasing problem of disease due to nonvaccin

299 Immunization with PCV7 has resulted in a substantial decline in pneumococc

300 ll responses to subsequent immunization with PCV7, when given after 23vP, were attenuated.